Lung Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LNG031 MIFTS: 51	Lung Benign Neoplasm Categories: Cancer diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm ¹² ¹⁵

Lung Neoplasms ⁴⁴ ⁷⁰

Tumor of the Lung ¹²

Lung Tumor ⁵⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3683

MeSH ⁴⁴ D008175

NCIt ⁵⁰ C3200

SNOMED-CT ⁶⁷ 126713003

UMLS ⁷⁰ C0024121

Sources

Summaries for Lung Benign Neoplasm

MalaCards based summary : Lung Benign Neoplasm, also known as lung neoplasms, is related to lung adenoma and carcinoid syndrome, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Sources

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 792)

#	Related Disease	Score	Top Affiliating Genes
1	lung adenoma	31.6	TP53 SFTPC SCGB1A1 RARB KRAS HRAS
2	carcinoid syndrome	31.5	SYP ENO2 CHGA
3	granular cell tumor	31.0	SYP NKX2-1 ENO2
4	glomus tumor	30.8	TP53 SYP ENO2 CDKN2A
5	desmoplastic small round cell tumor	30.7	SYP ENO2 CHGA
6	perivascular epithelioid cell tumor	30.7	SYP NKX2-1 CDKN2A
7	pulmonary sclerosing hemangioma	30.6	SYP NKX2-1 KRT7 ENO2 CHGA
8	rhabdoid cancer	30.5	TP53 SYP CDKN2A
9	sclerosing hemangioma	30.5	SYP NKX2-1 KRT7 ENO2 CHGA
10	malignant peripheral nerve sheath tumor	30.5	TP53 KRT7 EGFR CDKN2A
11	benign mesothelioma	30.5	NKX2-1 KRT7 KRT20 CDKN2A
12	myoblastoma	30.4	SYP ENO2
13	oncocytoma	30.4	SYP NKX2-1 KRT7 KRT20
14	hemangioblastoma	30.4	SYP ENO2 EGFR
15	pleomorphic rhabdomyosarcoma	30.3	TP53 SYP KRT7
16	epithelial-myoepithelial carcinoma	30.3	TP53 KRT7 HRAS
17	myoepithelial carcinoma	30.3	TP53 KRT7 HRAS
18	neuroendocrine tumor	30.3	SYP NKX2-1 KRT20 HRAS GRP ENO2
19	hemangioma	30.3	TP53 SYP NKX2-1 KRT7 KRAS ENO2
20	paraganglioma	30.2	SYP GRP ENO2 CHGA
21	pleomorphic adenoma	30.2	TP53 KRT7 HRAS CDKN2A
22	squamous cell papilloma	30.2	TP53 HRAS CDKN2A
23	myoma	30.2	TP53 KRAS EGFR
24	papillary adenocarcinoma	30.2	TP53 NKX2-1 KRT7
25	adenocarcinoma in situ	30.2	KRT7 KRT20 KRAS EGFR CDKN2A
26	pleural cancer	30.2	TP53 EGFR CDKN2A
27	alveoli adenoma	30.2	SFTPC SCGB1A1 NKX2-1
28	lymphoepithelioma-like carcinoma	30.2	KRT7 KRT20 ENO2 EGFR
29	tuberous sclerosis	30.1	TP53 SYP STK11 ENO2 CHGA
30	thymoma	30.1	TP53 SYP NKX2-1 HRAS EGFR
31	cystadenoma	30.1	SYP KRT7 KRT20 CHGA
32	appendix adenocarcinoma	30.1	SYP KRT7 KRT20 KRAS HRAS CHGA
33	skin benign neoplasm	30.1	KRT7 KRT20 HRAS ENO2
34	mucinous adenocarcinoma	30.1	TP53 NKX2-1 KRT7 KRT20 KRAS EGFR
35	in situ carcinoma	30.1	TP53 HRAS EGFR CDKN2A
36	neuroendocrine carcinoma	30.1	SYP NKX2-1 KRT7 KRT20 GRP ENO2
37	lung disease	30.1	TP53 SFTPC SCGB1A1 NKX2-1 GRP ENO2
38	exanthem	30.1	KRAS HRAS EGFR
39	mediastinal cancer	30.1	SYP NKX2-1 KRT7 ENO2 CHGA
40	sweat gland cancer	30.1	TP53 SYP KRT7 KRT20
41	bronchus cancer	30.0	GRP FHIT ENO2
42	carcinosarcoma	30.0	TP53 KRT7 KRAS HRAS EGFR CDKN2A
43	pulmonary adenocarcinoma in situ	30.0	SFTPC NKX2-1 KRAS HRAS EGFR
44	mucoepidermoid carcinoma	30.0	TP53 NKX2-1 KRT7 EGFR CHGA CDKN2A
45	kidney rhabdoid cancer	30.0	SYP ENO2
46	chordoma	30.0	TP53 KRT7 EGFR CDKN2A
47	transverse colon cancer	30.0	KRT7 KRT20 KRAS HRAS
48	malignant pheochromocytoma	30.0	SYP ENO2 CHGA
49	large cell neuroendocrine carcinoma	30.0	SYP NKX2-1 KRT7 KRT20 ENO2 EGFR
50	suppression of tumorigenicity 12	29.9	TP53 SYP HRAS EGFR CHGA CDKN2A

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:

Sources

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:

hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	CHGA EGFR HRAS KRAS KRT7 NQO1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

⁴⁶ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.33	CDKN2A CHGA EGFR FHIT GRP HRAS
2	growth/size/body region	MP:0005378	10.32	CDKN2A CHGA EGFR ENO2 GRP HRAS
3	cardiovascular system	MP:0005385	10.31	CDKN2A CHGA EGFR GRP HRAS KRAS
4	cellular	MP:0005384	10.3	CDKN2A EGFR ENO2 KRAS KRT7 NKX2-1
5	mortality/aging	MP:0010768	10.28	CDKN2A CHGA EGFR FHIT HRAS KRAS
6	endocrine/exocrine gland	MP:0005379	10.27	CDKN2A CHGA EGFR HRAS KRAS MGMT
7	digestive/alimentary	MP:0005381	10.21	CDKN2A EGFR FHIT HRAS KRAS NKX2-1
8	neoplasm	MP:0002006	10.18	CDKN2A EGFR FHIT HRAS KRAS MGMT
9	nervous system	MP:0003631	10.13	CDKN2A CHGA EGFR ENO2 GRP HRAS
10	muscle	MP:0005369	10.01	CDKN2A CHGA EGFR HRAS KRAS RARB
11	no phenotypic analysis	MP:0003012	9.96	CDKN2A CHGA EGFR HRAS KRAS MGMT
12	normal	MP:0002873	9.85	EGFR HRAS KRAS NKX2-1 RARB RASSF1
13	renal/urinary system	MP:0005367	9.61	CHGA EGFR HRAS KRAS KRT7 RARB
14	respiratory system	MP:0005388	9.44	CDKN2A EGFR ENO2 GRP HRAS KRAS

Sources

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 717)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Epinephrine

Approved, Vet_approved

Phase 4

51-43-4

5816

Racepinephrine

Approved

Phase 4

329-65-7

838

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Terbutaline

Approved

Phase 4

23031-25-6

5403

Ipratropium

Approved, Experimental

Phase 4

60205-81-4, 22254-24-6

43232 657309

Dexmedetomidine

Approved, Vet_approved

Phase 4

113775-47-6

5311068 68602

Dalteparin

Approved

Phase 4

9005-49-6

Heparin

Approved, Investigational

Phase 4

9005-49-6

772 9812414

Tinzaparin

Approved

Phase 4

9041-08-1, 9005-49-6

25244225

Remifentanil

Approved

Phase 4

132875-61-7

60815

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1

3821

Alfentanil

Approved, Illicit

Phase 4

71195-58-9

51263

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

12035

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Isoflurane

Approved, Vet_approved

Phase 4

26675-46-7

3763

Desflurane

Approved

Phase 4

57041-67-5

42113

Dabrafenib

Approved, Investigational

Phase 4

1195765-45-7

44462760 44516822

Olanzapine

Approved, Investigational

Phase 4

132539-06-1

4585 135398745

Tropisetron

Approved, Investigational

Phase 4

89565-68-4, 105826-92-4

5595

Acetaminophen

Approved

Phase 4

103-90-2

1983

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Osimertinib

Approved

Phase 4

1421373-65-0

71496458

afatinib

Approved

Phase 4

850140-72-6, 439081-18-2

10184653

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

126941

Vemurafenib

Approved

Phase 4

918504-65-1

42611257 23252090

Aspartic acid

Approved, Nutraceutical

Phase 4

56-84-8

5960

Imidacloprid

Vet_approved

Phase 4

105827-78-9

86418

Epinephryl borate

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agents

Phase 4

Adrenergic Agonists

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

calcium heparin

Phase 4

Opiate Alkaloids

Phase 4

N-Methylaspartate

Phase 4

Dopamine Uptake Inhibitors

Phase 4

Anesthetics, Dissociative

Phase 4

Bilirubin

Phase 4

635-65-4

5280352

N-monoacetylcystine

Phase 4

Anesthetics, Inhalation

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Antipsychotic Agents

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

Endostatins

Phase 4

71581480

Ibandronic Acid

Phase 4

L-Alanine

Nutraceutical

Phase 4

56-41-7

5950

Interventional clinical trials:

(show top 50) (show all 5405)

#	Name	Status	NCT ID	Phase	Drugs
1	The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) )	Unknown status	NCT01211002	Phase 4	radiotherapy / EP combined with recombinant human endostatin
2	Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study	Unknown status	NCT02348450	Phase 4	Irinotecan;Etoposide;Cisplatin
3	The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer	Unknown status	NCT02346318	Phase 4	Compound Kushen Injection
4	Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research	Unknown status	NCT02513355	Phase 4	Changchun marina;cisplatin;Taxol;parapl
5	Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD	Unknown status	NCT02504801	Phase 4	Budesonide
6	Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP	Unknown status	NCT03890055	Phase 4	Anlotinib Hydrochloride
7	A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)	Unknown status	NCT01028729	Phase 4	Endostar;Gemcitabine-Cisplatin chemotherapy
8	PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice	Unknown status	NCT00675168	Phase 4
9	A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer	Unknown status	NCT02195453	Phase 4	Yangzhengxiaoji Capsule;Placebo Capsule
10	Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin	Unknown status	NCT01336192	Phase 4	Gemcitabine;Best supportive care
11	Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study	Unknown status	NCT02194556	Phase 4	Sequential and maintenance icotinib;Maintenance icotinib
12	Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration	Unknown status	NCT01381627	Phase 4	Remifentanil;Dexmedetomidine
13	Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer	Unknown status	NCT02031601	Phase 4	Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
14	A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain	Completed	NCT01783236	Phase 4	IV Acetaminophen;Saline Placebo
15	A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients	Completed	NCT02744664	Phase 4	Icotinib
16	Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer.	Completed	NCT00925444	Phase 4
17	Comparing the Lozenge to the Patch for Smoking Cessation	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
18	"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study	Completed	NCT00338481	Phase 4	Morphine p.o.;Morphine s.c.
19	Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer	Completed	NCT02497118	Phase 4	Endostatin;Vinorelbine;Cisplatin
20	ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study	Completed	NCT03550482	Phase 4
21	A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan	Completed	NCT01196078	Phase 4	erlotinib [Tarceva];vinorelbine
22	Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation	Completed	NCT02962999	Phase 4	Ketamine;Saline
23	Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer.	Completed	NCT02316327	Phase 4	gemcitabine, cisplatin and bevacizumab
24	A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer	Completed	NCT01066884	Phase 4	erlotinib [Tarceva]
25	Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients	Completed	NCT01060137	Phase 4	fentanyl matrix
26	Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic	Completed	NCT00440960	Phase 4	propofol;midazolam;alfentanil;lidocaine
27	Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy	Completed	NCT00380718	Phase 4	pemetrexed
28	Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease	Completed	NCT02476526	Phase 4	Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
29	A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC).	Completed	NCT03853551	Phase 4	Osimertinib
30	Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer	Completed	NCT00451906	Phase 4	Platinum-based chemotherapy;Bevacizumab [Avastin]
31	A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC	Completed	NCT00115206	Phase 4	Neulasta® (pegfilgrastim)
32	A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis	Completed	NCT00099541	Phase 4	zoledronic acid
33	Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy	Completed	NCT01442909	Phase 4	Docetaxel and pemetrexed
34	A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy	Completed	NCT01230710	Phase 4	Erlotinib
35	Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial	Completed	NCT01741506	Phase 4	Dalteparin (Fragmin®)
36	Safety Study of Nivolumab for Selected Advanced Malignancies in India	Completed	NCT03444766	Phase 4	Nivolumab
37	A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy	Completed	NCT00770588	Phase 4	Gefitinib;Placebo
38	A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates	Completed	NCT00765687	Phase 4	bisphosphates
39	Enhancing Tobacco Use Treatment for African American Light Smokers	Completed	NCT00666978	Phase 4	bupropion hydrochloride
40	A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC)	Completed	NCT01317615	Phase 4	RAD001;Paclitaxel;Carboplatin
41	A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor	Completed	NCT01287754	Phase 4	erlotinib [Tarceva]
42	An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer	Completed	NCT00949910	Phase 4	Erlotinib
43	Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial.	Completed	NCT01658280	Phase 4
44	Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis	Completed	NCT00762346	Phase 4	zometa
45	A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung	Completed	NCT00747773	Phase 4
46	Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer	Completed	NCT00686322	Phase 4	Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
47	An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	Completed	NCT01000740	Phase 4
48	Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer	Completed	NCT00883675	Phase 4	Docetaxel-Carboplatin
49	Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer	Completed	NCT01020786	Phase 4	Pemetrexed;Carboplatin
50	Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)	Completed	NCT02151149	Phase 4	nab-paclitaxel;Carboplatin

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS ⁷⁰ / NDF-RT ⁵¹ :

Carboplatin

Carmustine

Cholecalciferol

Cisplatin

CISPLATIN PWDR

Cyclophosphamide

Etoposide

etoposide phosphate

Ifosfamide

Lomustine

Methotrexate

Methotrexate Sodium

Paclitaxel

Procarbazine

Procarbazine Hydrochloride

Teniposide

Vinblastine

Vinblastine Sulfate

Cochrane evidence based reviews: lung neoplasms

Sources

Genetic Tests for Lung Benign Neoplasm

Sources

Anatomical Context for Lung Benign Neoplasm

MalaCards organs/tissues related to Lung Benign Neoplasm:

⁴⁰

Lung, Brain, Lymph Node, Bone, T Cells, Liver, Prostate

Sources

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 1189)

#	Title	Authors	PMID	Year
1	GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. ⁶¹ ⁵⁴	Wang LJ...Resnick MB	19620839	2009
2	Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. ⁵⁴ ⁶¹	Hong HH...Sills RC	16395694	2007
3	Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. ⁵⁴ ⁶¹	Kren L...Ross JS	16506596	2006
4	Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. ⁶¹ ⁵⁴	Duan W...Villalona-Calero MA	15547185	2004
5	The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. ⁵⁴ ⁶¹	Chang YL...Wu CT	15084379	2004
6	Dysregulated secretoglobin expression in human lung cancers. ⁵⁴ ⁶¹	Sjodin A...Hedman H	12826312	2003
7	[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors]. ⁶¹ ⁵⁴	Yano S...Sone S	12652739	2003
8	Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. ⁵⁴ ⁶¹	Lyda MH...Weiss LM	10987260	2000
9	Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. ⁵⁴ ⁶¹	Gouyer V...Brambilla E	9476905	1998
10	Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. ⁵⁴ ⁶¹	Nguyen PL...Ho SB	8638091	1996
11	Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors. ⁵⁴ ⁶¹	Nickell-Brady C...Belinsky SA	7545909	1994
12	Expression of epidermal growth factor receptor in plutonium-239-induced lung neoplasms in dogs. ⁶¹ ⁵⁴	Gillett NA...Hahn FF	1313613	1992
13	[Usefulness of simultaneous antigenic determination of carcinoembryonic antigen (CEA), ferritin and orosomucoid levels in diagnosis of lung neoplasms]. ⁶¹ ⁵⁴	Sakowicz A...Wiatr E	1843646	1991
14	Prognostic factors in patients undergoing pulmonary resection for sarcomatoid carcinomas of the lung. ⁶¹	Ozkan B...Toker A	32988810	2021
15	Learning curve of robotic portal lobectomy for pulmonary neoplasms: A prospective observational study. ⁶¹	Yang MZ...Yang HX	33709571	2021
16	Fetal lung interstitial tumor: An uncommon pediatric pulmonary neoplasm. ⁶¹	Shah SN...Parameswaran A	33687015	2021
17	MRWMDA: A novel framework to infer miRNA-disease associations. ⁶¹	Wang M...Zhu P	33221377	2021
18	DF-MDA: an effective diffusion-based computational model for predicting miRNA-disease association. ⁶¹	Li HY...Li ZW	33429082	2021
19	Quantifying intratumor heterogeneity of lung neoplasms with radiomics. ⁶¹	Ferreira Junior JR...de Azevedo-Marques PM	33429143	2021
20	[Comprehensive genomic profiling in large cell neuroendocrine lung cancer: the times they are a-changin'.] ⁶¹	Filetti M...Giusti R	33512365	2021
21	Role of Omentin in Obesity Paradox in Lung Cancer. ⁶¹	Parida S...Sharma D	33450975	2021
22	Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors. ⁶¹	Chatzopoulos K...Boland JM	33409598	2021
23	Preoperative Body Weight and Albumin Predict Survival in Patients With Resectable Lung Neoplasms: Role of COPD. ⁶¹	Tang J...Barreiro E	32877328	2021
24	Comparison of preoperative scores predicting outcome in elderly undergoing lung malignancies resection. ⁶¹	Vaz Souza R...Anile M	33447396	2020
25	[Application of liquid biopsy in clinical practice: the importance of a scientific network for effective use of the biomolecular markers in NSCLC patient..] ⁶¹	MInelli M...Lugini A	33205777	2020
26	Mucous Gland Adenoma: The Spectrum of Growth Patterns and the Diagnostic Challenges. ⁶¹	Zaleski MP...Moran CA	32909967	2020
27	Surgical Treatment of Bilateral Lung Cancers: Long-Term Outcomes and Prognostic Factors. ⁶¹	Petrella F...Spaggiari L	30991418	2020
28	Predicting MiRNA-disease associations by multiple meta-paths fusion graph embedding model. ⁶¹	Zhang L...An J	33087064	2020
29	An Uncommon Lung Neoplasm in a Young Patient: Diagnostic Challenges. ⁶¹	Leser FS...Lapa E Silva JR	33060557	2020
30	Opening and closing the doors of the lockdown in Italy without forgetting lung cancer patients. ⁶¹	Bertolaccini L...Spaggiari L	32728692	2020
31	Primary lung neoplasms presenting as multiple synchronous lung nodules. ⁶¹	Ghosh S...Farver C	32878970	2020
32	NEMPD: a network embedding-based method for predicting miRNA-disease associations by preserving behavior and attribute information. ⁶¹	Ji BY...Yi HC	32912137	2020
33	Deep-belief network for predicting potential miRNA-disease associations. ⁶¹	Chen X...Zhu CC	32866969	2020
34	Angioleiomyoma of the pulmonary artery: a case report and literature review. ⁶¹	Hu Y...Liu W	32859240	2020
35	PD-1/PD-L1 negative schwannoma mimicking obstructive bronchial malignancy: A case report. ⁶¹	Zhou D...Gong Y	32510862	2020
36	[The development and validation of risk prediction model for lung cancer: a systematic review]. ⁶¹	Lyu ZY...He J	32268653	2020
37	Diagnostic yield of rapid on-site evaluation transbronchial needle aspiration versus conventional transbronchial needle aspiration: a single center experience. ⁶¹	Guarino C...Salvi R	32293166	2020
38	CT Halo sign: A systematic review. ⁶¹	Ray A...Vyas S	32007819	2020
39	SAEROF: an ensemble approach for large-scale drug-disease association prediction by incorporating rotation forest and sparse autoencoder deep neural network. ⁶¹	Jiang HJ...You ZH	32188871	2020
40	Diffusion-Weighted MR Imaging of Primary and Secondary Lung Cancer: Predictive Value for Response to Transpulmonary Chemoembolization and Transarterial Chemoperfusion. ⁶¹	Vogl TJ...Albrecht MH	31899107	2020
41	Psychosocial interventions for informal caregivers of lung cancer patients: A systematic review. ⁶¹	Kedia SK...Jackson BM	31701588	2020
42	Alternative and New Radiopharmaceutical Agents for Lung Cancer. ⁶¹	Telo S...Fanti S	31868150	2020
43	Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review. ⁶¹	Theodoropoulos AS...Tolia M	33062275	2020
44	Chance to rein in a cancer--Spontaneous regression of lung carcinoma (1988-2018): a 30-year perspective. ⁶¹	Zhang J...Qian H	32509094	2020
45	A Rare Cause of Cough: Tracheobronchial Myxoid Spindle Cell Lipoma. ⁶¹	Rodriguez JA...Ramirez JF	32551146	2020
46	Classification and Imaging Findings of Lung Neoplasms. ⁶¹	Altmayer S...Hochhegger B	31964479	2020
47	mTOR in Lung Neoplasms. ⁶¹	Krencz I...Khoor A	32016810	2020
48	CT-based radiomics for prediction of histologic subtype and metastatic disease in primary malignant lung neoplasms. ⁶¹	Ferreira-Junior JR...de Azevedo-Marques PM	31722085	2020
49	A Computational Study of Potential miRNA-Disease Association Inference Based on Ensemble Learning and Kernel Ridge Regression. ⁶¹	Peng LH...Piao X	32117922	2020
50	Bronchial Carcinoid Tumors with Massive Osseous Metaplasia: A Case Report and Review of the Literature. ⁶¹	Ozsen M...Gokalp G	30977863	2020

Sources

Genes for Lung Benign Neoplasm

Genes related to Lung Benign Neoplasm (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NKX2-1	NK2 Homeobox 1	Protein Coding	16.47	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11668468 15098255 12930693 (more) 19620839 11957142 15257545 16540736 10721419 15084379 12011259 19740516 12407752 10895813 14745718 17425388 18801593 11679943 16570563 19747750
2	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	15.55	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11528387 16410370 12650907 (more) 17510423 11559534 15753357 20101149 19887599 17693665 11016621 15572290 15026325 15021904
3	TP53	Tumor Protein P53	Protein Coding	15.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	12907609 10446974 15805253 (more) 9255578 8142008 17477876 8600505 10706103 19072763 18712569 8614143 12591728 1543544 11559534 12650907 15902970 1656762 16865671 12552590 8623922 16288016 8137262 15564288 10861503 7586163 8504472 2223098 18006810 19941079 10207632 12711114 10350439 16410370 1620551 8353844 8170984 8014012 7969181 16934800 10953344 10353731 9230291 9052408 9052381 20514470 18555750 17530187 17007887 9289861 8959323 8389245 1444195 1312896 17409930 17380445 16247444 15564291 19995647 17693665 16482519 11726024 11414196 11107065 7923210 1331352 19639960 16472094 15547185 10475393 10223567 10091733 9784987 9675232 16458448 15072824 12844488 11815976 11474498 11195464 10368638 15572290 9637795 8843680 7545909 8317547 1486840 18292798 14617796 13679864 10937049 10100998 9307295 19434453 19188169 16395694 11035769 16675590 7855100 7677185
4	EGFR	Epidermal Growth Factor Receptor	Protein Coding	13.83	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	1313613 17477876 19088172 (more) 18271921 17927446 20207772 7855100 12631609 12652739 15032719 15753357 16467080 18030469 15489898 15476598 11879619 19723643 19155297 18651255 16642476 17889445 19328671 20007486 19168569 19289583 18992960 12711118 8297109 19887599 19995647 17913856 17052260 16540667 16730237 9703905 17256054 16198442 18721806 17369752 18093943 19096299 1356016 14757534 16230409
5	SCGB1A1	Secretoglobin Family 1A Member 1	Protein Coding	13.28	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	12826312 1394139 9191473
6	KRT7	Keratin 7	Protein Coding	12.46	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11668468 16570563 11745209 (more) 11679943 10987260 12930693 20432971
7	SFTPC	Surfactant Protein C	Protein Coding	12.41	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	1394139 7524342 16085219 (more) 8248207
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	12.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	9054597 9659580 15455389 (more) 11872642 16533425 9589349 9032263 9659578 16482519 9816033 16543296 19440353 10649246 8758904 9731504 16705183 12185599 9659583 11414196 11920642 17140695 15073103
9	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	11.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	8620533 9393735 19935706 (more) 8653678 9740075 12007194 19418484 14731325 17693665 19096006 17140695 17255269 9850082 19267103
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	11.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	16410370 19440353 18758463
11	SYP	Synaptophysin	Protein Coding	11.36	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	10987260 11417996 2170973
12	RARB	Retinoic Acid Receptor Beta	Protein Coding	11.02	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	10834944 17140695 14656941 (more) 10944551 20484175 1717924
13	RASSF1	Ras Association Domain Family Member 1	Protein Coding	10.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	17477876 11306494 15711568 (more) 11668500 15073103 16543296
14	CHGA	Chromogranin A	Protein Coding	10.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	1668786 8427030 11417996 (more) 2170973
15	ENO2	Enolase 2	Protein Coding	10.49	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	7564279 8616474 18998332 (more) 9329552
16	KRT20	Keratin 20	Protein Coding	10.43	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11668468 18626520 16570563 (more) 20432971 12011259 11679943 11745209
17	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	10.25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	10069465 18712569 16533425 (more) 9714064 18555750 15073103 12185595
18	GRP	Gastrin Releasing Peptide	Protein Coding	10.23	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	1698239 1668786 8718793 (more) 8132585 1752059 15750618
19	STK11	Serine/Threonine Kinase 11	Protein Coding	9.89	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	19176640 17521700 19229701 (more) 15077168 15021901
20	NQO1	NAD(P)H Quinone Dehydrogenase 1	Protein Coding	9.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	12370763 9748120 1324793 (more) 8195022 8205540 1908440 8221686
21	NCAM1	Neural Cell Adhesion Molecule 1	Protein Coding	9.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	9777989 20191608 8194895 (more) 1314782 2153450
22	TERT	Telomerase Reverse Transcriptase	Protein Coding	9.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	15837730 16202213 19010833
23	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	9.76	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	14737093 19723643
24	CASP3	Caspase 3	Protein Coding	9.54	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	19238186 16144019 16902813
25	RB1	RB Transcriptional Corepressor 1	Protein Coding	9.52	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	9659580 12612881 7855100 (more) 11030152 16613540 10649246 9659583 8758904 7923210 10475393 9589349 9476905
26	NUDT1	Nudix Hydrolase 1	Protein Coding	9.25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	15126288
27	CTSB	Cathepsin B	Protein Coding	9.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11147599 2320181 8074490 (more) 7612192 1674512 8074469 16380983 9402478 8402725 15878337 8014475
28	PTGIS	Prostaglandin I2 Synthase	Protein Coding	8.97	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	19138979 15313935
29	AKR1C1	Aldo-Keto Reductase Family 1 Member C1	Protein Coding	8.93	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	17163506 16876904

Sources

Variations for Lung Benign Neoplasm

Sources

Expression for Lung Benign Neoplasm

Search GEO for disease gene expression data for Lung Benign Neoplasm.

Sources

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁶	12.58	TP53 RASSF1 RARB NQO1 KRAS HRAS
2	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.53	TP53 RARB NQO1 KRAS HRAS EGFR
3	mTOR signaling pathway (KEGG) ³⁶ Show member pathways mTOR Signaling Pathway ⁶⁴	12.39	TP53 STK11 KRAS HRAS EGFR
4	MicroRNAs in cancer ³⁶	12.37	TP53 RASSF1 KRAS HRAS EGFR CDKN2A
5	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.36	TP53 RASSF1 RARB KRAS HRAS FHIT
6	Human T-cell leukemia virus 1 infection ³⁶	12.27	TP53 KRAS HRAS CDKN2A
7	Proteoglycans in cancer ³⁶	12.23	TP53 KRAS HRAS EGFR
8	Viral carcinogenesis ³⁶	12.22	TP53 KRAS HRAS CDKN2A
9	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²³ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁵ Immune response Oncostatin M signaling via MAPK in human cells ²³ MAPK Cascade ¹ Nanoparticle-mediated activation of receptor signaling ¹ Oncostatin M Signaling Pathway ¹	12.22	TP53 KRAS HRAS EGFR
10	Cellular senescence (KEGG) ³⁶	12.08	TP53 KRAS HRAS CDKN2A
11	Integrated Breast Cancer Pathway ¹	12.06	TP53 STK11 KRAS EGFR
12	Longevity regulating pathway ³⁶ Show member pathways Longevity regulating pathway - multiple species ³⁶	12.03	TP53 STK11 KRAS HRAS
13	UVA-Induced MAPK Signaling ⁶³ Show member pathways UVB-Induced MAPK Signaling ⁶³	11.99	TP53 KRAS HRAS EGFR
14	FoxO signaling pathway ³⁶ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.97	STK11 KRAS HRAS EGFR
15	DNA Damage Response (only ATM dependent) ¹	11.86	TP53 KRAS HRAS CDKN2A
16	Mitophagy - animal ³⁶	11.63	TP53 KRAS HRAS
17	Central carbon metabolism in cancer ³⁶	11.58	TP53 KRAS HRAS EGFR
18	Agrin Interactions at Neuromuscular Junction ⁶³	11.54	KRAS HRAS EGFR
19	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.48	TP53 EGFR CDKN2A
20	Glioblastoma Multiforme ⁶³	11.48	TP53 MGMT KRAS HRAS EGFR CDKN2A
21	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.37	KRAS HRAS EGFR
22	Aryl Hydrocarbon Receptor ¹	11.35	NQO1 KRAS HRAS EGFR
23	Extracellular vesicle-mediated signaling in recipient cells ¹	11.16	KRAS HRAS EGFR
24	G-protein signaling_K-RAS regulation pathway ²³	11.08	RASSF1 KRAS EGFR
25	EGFR Transactivation by Gastrin ⁶⁵ Show member pathways EGFR-dependent Endothelin signaling events ¹ SHC-related events triggered by IGF1R ⁶⁵	11.05	KRAS HRAS EGFR
26	Bladder cancer ³⁶ ¹	10.96	TP53 RASSF1 KRAS HRAS EGFR CDKN2A

Sources

GO Terms for Lung Benign Neoplasm

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.88	TP53 NKX2-1 KRAS HRAS CDKN2A
2	negative regulation of cell proliferation	GO:0008285	9.85	TP53 STK11 RARB HRAS CDKN2A
3	apoptotic process	GO:0006915	9.85	TP53 STK11 KRT20 HRAS FHIT CDKN2A
4	positive regulation of MAP kinase activity	GO:0043406	9.58	KRAS HRAS EGFR
5	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.49	TP53 EGFR
6	response to isolation stress	GO:0035900	9.43	KRAS HRAS
7	intrinsic apoptotic signaling pathway by p53 class mediator	GO:0072332	9.43	TP53 STK11 FHIT
8	cell cycle arrest	GO:0007050	9.35	TP53 STK11 RASSF1 HRAS CDKN2A
9	regulation of long-term neuronal synaptic plasticity	GO:0048169	9.33	SYP KRAS HRAS
10	positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway	GO:1900738	9.32	GRP CHGA
11	Ras protein signal transduction	GO:0007265	9.02	TP53 RASSF1 KRAS HRAS CDKN2A

Molecular functions related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.56	TP53 SYP SFTPC RASSF1 NQO1 KRAS
2	p53 binding	GO:0002039	9.33	TP53 STK11 CDKN2A
3	MDM2/MDM4 family protein binding	GO:0097371	9.26	TP53 CDKN2A
4	LRR domain binding	GO:0030275	8.62	STK11 KRAS

Sources

Sources for Lung Benign Neoplasm

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia

Lung Benign Neoplasm

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Classifications:

External Ids:

Summaries for Lung Benign Neoplasm

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Cochrane evidence based reviews: lung neoplasms

Genetic Tests for Lung Benign Neoplasm

Anatomical Context for Lung Benign Neoplasm

MalaCards organs/tissues related to Lung Benign Neoplasm:

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

Genes for Lung Benign Neoplasm

Genes related to Lung Benign Neoplasm (0 elite genes):

Variations for Lung Benign Neoplasm

Expression for Lung Benign Neoplasm

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

GO Terms for Lung Benign Neoplasm

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

Molecular functions related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

Sources for Lung Benign Neoplasm

Inferred drug relations via UMLS ⁷⁰ / NDF-RT ⁵¹ :